key: cord-0889934-zmwuu35x authors: Enikeev, Dmitry; Taratkin, Mark; Morozov, Andrey; Petov, Vladislav; Korolev, Dmitry; Shpikina, Anastasia; Spivak, Leonid; Kharlamova, Svetlana; Shchedrina, Irina; Mestnikov, Oleg; Fiev, Dmitry; Ganzha, Timur; Geladze, Marina; Mambetova, Aichurok; Kogan, Evgenia; Zharkov, Nikolay; Demyashkin, Gregory; Shariat, Shahrokh F.; Glybochko, Petr title: Prospective two‐arm study of the testicular function in patients with COVID‐19 date: 2022-02-19 journal: Andrology DOI: 10.1111/andr.13159 sha: 5dc1c1ff56fdf81c3d9bc294e07d21e9148b2f0a doc_id: 889934 cord_uid: zmwuu35x BACKGROUND: The COVID‐19 pandemic has led the international community to conduct extensive research into potential negative effects of the disease on multiple organs and systems in the human body. One of the most discussed areas is potential of the virus to compromise the testicular function. However, the lack of prospective studies on this topic makes it impossible to draw reliable conclusions on whether the disease affects the male reproductive system and, if so, to what extent. OBJECTIVES: The current trial is aimed at investigating the effect of SARS‐CoV‐2 on the testicular function, hormone levels and determining the extent of impact on spermatogenesis and damage to testicular tissue. MATERIALS AND METHODS: This prospective study included healthy controls and cases of patients suffering from viral pneumonia based on chest computed tomography (CT) and a positive SARS‐CoV‐2 throat swab exhibited moderate symptoms (World Health Organization (WHO) classification). Epidemiological, clinical, laboratory and ultrasound data were collected. A semen analysis was performed in cases during their hospital stay and 3 months after the discharge home. We also assessed the testicles obtained during autopsies of patients who died of COVID‐19 (n = 20). RESULTS: A total of 88 participants were included (44 controls and 44 cases). Blood testosterone levels were significantly decreased in 27.3% of the cases (12/44). The mean level (7.3±2.7 nmol/L) was lower than that in the healthy controls (13.5±5.2 nmol/L, p < 0.001). An increase in luteinizing hormone (LH) and follicle‐stimulating hormone (FSH) was also detected compared to the healthy controls (p = 0.04 and p = 0.002). The semen analysis revealed decreased motility in COVID‐19 patients (p = 0.001), and a higher number of immobile sperm (during COVID‐19: 58.8% and at 3 months 47.4%, p = 0.005). All parameters returned to normal at 3 months after discharge. Direct mixed agglutination reaction (MAR) test at 3 months showed an increase of Ig A (p = 0.03). In the majority of autopsies (18/20), structural disorders of the testicular tissue, with signs of damage to germ cells were observed. DISCUSSION AND CONCLUSION: COVID‐19 and its management strategies significantly affect male hormone levels and sperm quality at the onset of the disease. Postmortem examination of testicular tissue confirmed inflammation and viral infiltration of the testicles. However, in patients with moderate to severe disease, the studied parameters of the testicular function returned to normal values within 3 months. agglutination reaction (MAR) test at 3 months showed an increase of Ig A (p = 0.03). In the majority of autopsies (18/20) , structural disorders of the testicular tissue, with signs of damage to germ cells were observed. Discussion and conclusion: COVID-19 and its management strategies significantly affect male hormone levels and sperm quality at the onset of the disease. Postmortem examination of testicular tissue confirmed inflammation and viral infiltration of the testicles. However, in patients with moderate to severe disease, the studied parameters of the testicular function returned to normal values within 3 months. and Sertoli cells) which makes them potential targets for the virus. 5 In fact, there are reports of orchitis and epididymitis in patients diagnosed with COVID-19, 6 which may suggest that SARS-CoV-2 is able to directly damage testicular tissue potentially compromising male fertility and hormone function. To date, there has not been a focused study of hormonal levels and inflammatory markers in the semen and testicular tissues. It has been suggested that COVID- 19 show that the COVID-19 infection often leads to a decrease in testosterone levels and may affect semen quality. 7, 8 However, the small size and retrospective nature of the previous studies render any conclusive statements impossible for now. Moreover, a large percentage of the available research separately assessed a limited number of parameters in isolation-such as hormone levels, sperm quality, testicular pathology, without adequate controls. There is ultimately too little information to draw reliable conclusions regarding the effects of the virus on male reproduction. Published reports are limited by small study groups, lack of the control group, and the absence of follow-up examinations during recovery warranting further research and in-depth exploration of the topic. 9 The current prospective series is aimed at investigating the effect of SARS-CoV-2 on the testicular function and determining the extent of damage to testicular cells. The trial was powered to detect changes in semen analysis (sperm motility, morphology, and count). The sample size calculation was based on the finding that decreased semen quality could be found in almost 50% of otherwise healthy males. 10 According to the available data, semen quality deteriorated in 20%-30% of patients with COVID- 19. 11 Therefore, we suggested that based on non-inferiority sample size calculation, a total of 70 patients should be included in the study for 80% statistical power with the upper limit of a one-sided 95% confidence interval exceeding a > 30% difference in favor of the standard treatment group. Considering a drop-off rate of 20%, 88 study participants were planned to be included (44 patients per cohort). Epidemiological, clinical (i.e., disease severity and symptoms, glucocorticoid use), and ultrasound data (color Doppler ultrasound of the scrotum) were collected during admission and in 3 months. All ultrasound tests were performed by a single highly-experienced urologist. All the tests, both during hospital stay and 3 months after (semen anal- To conduct a comprehensive trial providing evidence on both functional and structural changes in the testicles of patients with COVID-19, a separate cohort of patients who died from COVID-19 was created. As it was planned to collect the semen samples from those recovering from moderate-to-severe disease, we expected that none of the participants from the main cohort would be included into the pathology cohort. However, to increase homogeneity of the results the inclusion criteria for the pathology cohort were the same as those for the main cohort (in short, positive RT-PCR, no history of infertility or hypogonadism, etc., age up to 65 years). The additional informed consent for the pathology assessment was obtained from relatives of the deceased. The cohort size (20 patients) was calculated based on the previous studies on this topic to represent a valuable addition to available data. 13, 14 Testicles were collected from deceased patients for an autopsy for For statistical analysis, we used SPSS Statistics 23.0 (IBM, USA). The pathology cohort results were assessed using descriptive statistics in Excel 365 (Microsoft, USA). Categorical variables were described in terms of frequency and percentage, and continuous variables were described using mean, standard deviation, median, and interquartile range (IQR) values. When the data were normally distributed, independent t-tests or ANOVA were employed to compare the mean of continuous variables. Otherwise, the Mann-Whitney test was used. Categorical variables were compared using Pearson's chi-squared test. Non-categorical variables were compared using Spearman's correlation coefficient. A two-sided p-value of 0.05 was considered the threshold for statistical significance. Blood tests revealed that the testosterone level was below normal The semen analysis revealed increased sperm concentration All the patients underwent ultrasound and color Doppler of the scrotum while in the hospital (to exclude from analysis those with significant varicocele) and at 3 months after discharge. No specific changes were observed during the hospital stay or at 3 months after discharge. No changes in blood flow on color Doppler were found (Table 3) Mean age in the autopsy cohort was 50.5±10.6 (35-65 The current study showed that male patients with moderate to severe As for pathology findings, the examination of the testicles of 20 Another point highlighted in the article is transmission of SARS-CoV-2 through semen. Our study did not aim at detecting viral presence in semen. However, it should be noted that we were able to identify the viral presence with RT-PCR in all the pathology samples obtained. Despite the previous results suggesting prominent changes even after discharge, which were similar to our findings (percentage of progressive motility, and normal sperm morphology after COVID-19 and decline in the testosterone level 350.1 ± 115.5 vs. 289.8 ± 103.3 ng/dl, p = 0.009), 21 we found that the adverse effects of COVID-19 on the sperm quality last no longer than 3 months. However, the abovementioned effects are still a matter for discussion but the effect of corticosteroids on male hypogonadism has been reported previously. 22 The general decrease in the semen analysis results observed in our trial is similar to those of previous epidemiological studies. 23 Sperm quality is decreasing among certain (ethnic) groups around the world. This trend appears to be particularly prevalent in big cities. 23 When we designed this study, we expected that the use of reference values alone would not allow us to conclude whether the abnormal results are due to COVID-19, or a decrease found in the population of a specific region. Therefore, we expected the reference cohort to shed light on the real-life sperm quality in the local population. Moreover, we observed that the majority of the hormone and semen analysis results did not differ at 3-month follow-up in the COVID-19 cohort from those of healthy participants. However, these results should be used carefully especially when applying them to other parts of the world. Limitations. Among the study limitations is the small number of participants and the absence of data on those in whom both the sperm test and pathology results are available. Yet we believe that these findings will shed a little light on the fertility of patients who survived COVID-19. Our study in turn provides substantial data on those who recovered from COVID-19 and despite a relatively small number of participants was powered to detect possible changes in sperm tests. COVID-19 and its management significantly affect male hormone levels and sperm quality during the disease onset. Postmortem examination of testicular tissue confirmed inflammation and viral infiltration of the testicles. However, in patients with moderate to severe disease, the negative effect of SARS-CoV-2 on the testicular function vanishes within 3 months. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Does SARS-cov-2 infect the kidney? Multiorgan and renal tropism of SARS-CoV-2 Acute kidney injury in COVID-19: Are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19 scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, leydig and sertoli cells A coronavirus disease 2019 (COVID-19) patient with bilateral orchitis Coronavirus disease and male fertility: A systematic review Male fertility and the COVID-19 pandemic: Systematic review of the literature Effects of infection with SARS-CoV-2 on the male and female reproductive systems: A review WHO manual for the standardized investigation and diagnosis of the infertile couple Assessment of SARS-CoV-2 in human semen-A cohort study Disease severity classification and covid-19 outcomes, Republic of Korea Pathological findings in the testes of COVID-19 patients: Clinical implications Testicular pathology in fatal COVID-19: A descriptive autopsy study Hematological findings and complications of COVID-19 COVID-19 disrupts the blood-testis barrier through the induction of inflammatory cytokines and disruption of junctional proteins Serum IgA, IgM, and IgG responses in COVID-19 Redox-modulating agents in the treatment of viral infections Impaired spermatogenesis in COVID-19 patients SARS-CoV-2 and its relationship with the genitourinary tract: Implications for male reproductive health in the context of COVID-19 pandemic Does COVID-19 worsen the semen parameters? Early results of a tertiary healthcare center Effect of exogenous glucocorticoids on male hypogonadism Prospective two-arm study of testicular function in patients with COVID-19 The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.